s-methadone
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 27, 2024 (NCT06735079)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glutamate NMDA receptorANTAGONIST
Glutamate NMDA receptor
- Glutamate receptor ionotropic, NMDA 1 (Grin1) ↗
- Glutamate receptor ionotropic, NMDA 2A (Grin2a) ↗
- Glutamate receptor ionotropic, NMDA 2B (Grin2b) ↗
- Glutamate receptor ionotropic, NMDA 2C (Grin2c) ↗
- Glutamate receptor ionotropic, NMDA 2D (Grin2d) ↗
- Glutamate receptor ionotropic, NMDA 3B (Grin3b) ↗
- Glutamate receptor ionotropic, NMDA 3A (Grin3a) ↗
- Glutamate [NMDA] receptor subunit epsilon 4
- Glutamate [NMDA] receptor subunit epsilon 1
- Glutamate [NMDA] receptor subunit epsilon 2
- Glutamate (NMDA) receptor subunit zeta 1
- Glutamate [NMDA] receptor subunit 3A
- Glutamate [NMDA] receptor subunit epsilon 3
- Glutamate NMDA receptor; Grin1/Grin2b
- Glutamate NMDA receptor; Grin1/Grin2a
- Glutamate NMDA receptor; Grin1/Grin2c
- Ionotropic glutamate receptor NMDA 1/2D
- Ionotropic glutamate receptor NMDA1/2A/2B
Chemistry & pharmacology
Loading structure…
SMILES
CCC(=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1- Mol. weight
- 309.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL350719 ↗
Also known as
- s-methadone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06735079 | Phase 3 | Dec 27, 2024 | MGGM LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MGGM LLC | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1